Salud financiera de hoja de balance de Ovid Therapeutics
Salud financiera controles de criterios 6/6
Ovid Therapeutics has a total shareholder equity of $88.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $118.1M and $29.2M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$76.97m |
| Patrimonio | US$88.90m |
| Total pasivo | US$29.19m |
| Activos totales | US$118.09m |
Actualizaciones recientes sobre salud financiera
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Recent updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics: Good Entry Point For Investors
Jun 18Ovid Therapeutics appoints Jeff Rona as CFO
Jun 04Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Revisiting Ovid Therapeutics
Jan 14Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 01Análisis de la situación financiera
Pasivos a corto plazo: OVID's short term assets ($80.9M) exceed its short term liabilities ($14.1M).
Pasivo a largo plazo: OVID's short term assets ($80.9M) exceed its long term liabilities ($15.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: OVID is debt free.
Reducción de la deuda: OVID has not had any debt for past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: OVID has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: OVID has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 0.4% each year.